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Introduction
A subset of patients, of unknown percentage, fail to
respond to TNFa blockers or are unable to tolerate these
therapies and may therefore benefit from switching to
another drug.
Objectives
To report the evidence regarding the effectiveness of
switching to another anti-TNFa treatment in children
with childhood autoimmune chronic uveitis (ACU),
failure/refractory to the first course of anti-TNFa
treatment.
Methods
A systematic search between January 2000 and May 2013
was conducted using EMBASE, Ovid MEDLINE, Evidence
Based Medicine Reviews-ACP Journal Club, Cochrane
libraries, and EBM Reviews. Studies investigating the effi-
cacy of anti-TNFa therapy, as the second biologic treat-
ment for ACU, in children (≤16 yrs) refractory to a first
course of a single anti-TNFa treatment, topical and/or
systemic steroid therapy and at least one DMARD, were
eligible for inclusion. The primary outcome measure was
the improvement of intraocular inflammation, as defined
by the SUN working group criteria, at 6 (± 2) month
follow-up on treatment.
Results
zAmong 1086 identified articles, 128 were scrutinized:
10 observational studies, 7 on Adalimumab (ADA), 4 on
Infliximab (INF), were deemed eligible, including 40
children (ADA n = 34, INF n = 6). JIA was the most
common disease: 39 out 40 cases (97.5%).Seven-teen
children received Etanercept: 11 were switched to ADA,
the remaining 6 to INF. All the 23 children previously
received INF were switched to ADA. Altogether, 30 chil-
dren (24 on ADA, 6 on INF) out of 40 responded to
treatment, and the proportion of participants with a
positive response ranged from 43% to 100% individual
studies.The pooled analysis suggested that a second anti
TNFa treatment with ADA and INF has a favorable
effect in the improvement of intraocular inflammation:
0.75 (95% CI: 0.67-0.81) was the combined estimate of
the proportion of subjects improving All 6 children who
received INF after a previous failure to a course of ETA,
responded. Eight out of eleven (72.7%) children with a
previous failure ETA, and 16 out 23 (69.5%) with a
previous failure to INF, responded to a second course of
anti TNFa treatment with ADA.Eighteen chidlren on
ADA and all 6 on INF have been able to tape and/or
discontinue systemic steroid administration; disconti-
nuation/tapering of concomitant DMARD therapy was
possible for 7 out of 19 children receiving ADA, 3 out
of 4 children receiving INF. Four eligible papers did not
report extractable data regarding visual outcome. Nine
of 11 children (73%) showed improvement or stable
normal visual acuity post ADA treatment, and 5 out of
6 children (79.3%) after INF. Among 33 anti-TNFa
exposed children, data regarding side effects were not
available from 2 studies (n = 7), 6 (25.2%) experienced
adverse events: 5 while on ADA (all 5 complaining pain
discomfort and/or local reactions), 1 on INF, who
experienced a transient broncospastic cough.
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Conclusion
Switching between anti-TNFa obtains an overall probabil-
ity of improvement of intraocular inflammation in 75%
children affected by refractory ACU. No switching has
been reported to ETA, all children received ADA or INF
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